| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 55700-0627-12 | 55700-0627 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 18, 2018 | In Use | |
| 68788-8582-02 | 68788-8582 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 12, 2024 | In Use | |
| 60687-0428-01 | 60687-0428 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Sep 9, 2019 | In Use | |
| 00409-4755-11 | 00409-4755 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Oct 24, 2014 | Oct 16, 2017 | In Use |
| 69639-0103-01 | 69639-0103 | Palonosetron hydrochloride | Aloxi | 0.05 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Nov 1, 2018 | Nov 1, 2022 | No Longer Used |
| 23155-0549-31 | 23155-0549 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Jun 15, 2012 | In Use | |
| 00517-0745-01 | 00517-0745 | Pamidronate Disodium | Pamidronate Disodium | 3.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Jul 16, 2010 | Aug 24, 2012 | No Longer Used | |
| 00069-1305-10 | 00069-1305 | epoetin alfa-epbx | RETACRIT | 2000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 18, 2018 | In Use | ||
| 67457-0148-10 | 67457-0148 | Mesna | Mesna | 100.0 mg/mL | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | Apr 3, 2012 | Sep 30, 2016 | No Longer Used |
| 59676-0303-02 | 59676-0303 | Erythropoietin | Procrit | 3000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 1, 1989 | Jan 8, 2014 | In Use | |
| 61919-0465-10 | 61919-0465 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 1, 2014 | In Use | |
| 68554-3025-04 | 68554-3025 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Mar 4, 2016 | In Use | |
| 00378-5036-93 | 00378-5036 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Oct 20, 2015 | Jun 30, 2019 | No Longer Used |
| 59676-0304-01 | 59676-0304 | Erythropoietin | Procrit | 4000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 1, 1989 | In Use | ||
| 42291-0257-90 | 42291-0257 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov 30, 2015 | Nov 1, 2018 | No Longer Used |
| 60505-6193-04 | 60505-6193 | Palonosetron Hydrochloride | Palonosetron | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Sep 19, 2018 | In Use | |
| 00172-5240-70 | 00172-5240 | Anagrelide Hydrochloride | Anagrelide Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Platelet-Reducing Agent | PDE-3 Inhibitor | Oral | Apr 18, 2005 | Jun 9, 2009 | In Use |
| 55513-0267-01 | 55513-0267 | Epoetin alfa | Epogen | 3000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Apr 30, 1990 | In Use | ||
| 47335-0715-83 | 47335-0715 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov 25, 2022 | No Longer Used | |
| 60505-0133-00 | 60505-0133 | Cyclosporine | Cyclosporine | 25.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | May 29, 2002 | In Use | |
| 33261-0417-12 | 33261-0417 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 31, 2007 | In Use | |
| 52125-0334-14 | 52125-0334 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Aug 11, 2014 | Apr 27, 2017 | No Longer Used |
| 63187-0636-10 | 63187-0636 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 2, 2016 | In Use | |
| 55513-0144-01 | 55513-0144 | Epoetin alfa | Epogen | 10000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug 16, 1993 | In Use | ||
| 53217-0300-12 | 53217-0300 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | In Use |
Found 11765 results — Export these results
Home